WO2009124553A3 - Utilisation de médicaments induisant une hypothermie - Google Patents
Utilisation de médicaments induisant une hypothermie Download PDFInfo
- Publication number
- WO2009124553A3 WO2009124553A3 PCT/DK2009/000092 DK2009000092W WO2009124553A3 WO 2009124553 A3 WO2009124553 A3 WO 2009124553A3 DK 2009000092 W DK2009000092 W DK 2009000092W WO 2009124553 A3 WO2009124553 A3 WO 2009124553A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ischemia
- treatment
- cannabinoid receptor
- receptor agonists
- inducing drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur l'utilisation d'un agoniste de récepteur cannabinoïde pour une utilisation dans l'induction d'une hypothermie chez un être humain pour la prophylaxie et le traitement d'une ischémie.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200800515 | 2008-04-09 | ||
DKPA200800515 | 2008-04-09 | ||
DKPA200801141 | 2008-08-21 | ||
DKPA200801141 | 2008-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009124553A2 WO2009124553A2 (fr) | 2009-10-15 |
WO2009124553A3 true WO2009124553A3 (fr) | 2009-12-03 |
Family
ID=41130582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2009/000092 WO2009124553A2 (fr) | 2008-04-09 | 2009-04-08 | Utilisation de médicaments induisant une hypothermie |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009124553A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007150010A2 (fr) | 2006-06-23 | 2007-12-27 | Abbott Laboratories | Dérivés de cyclopropylamines |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
US8608696B1 (en) | 2009-02-24 | 2013-12-17 | North Carolina State University | Rapid fluid cooling devices and methods for cooling fluids |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837228A (en) * | 1979-05-31 | 1989-06-06 | The University Of Mississippi | Antiinflammatory and antimicrobial compounds and compositions |
WO2001024645A1 (fr) * | 1999-10-07 | 2001-04-12 | Societe Des Produits Nestle S.A. | Composition nutritionnelle |
WO2004004702A2 (fr) * | 2002-07-09 | 2004-01-15 | The Scripps Research Institute | Procede pour empecher les lesions par ischemie et reperfusion |
US20040229850A1 (en) * | 2003-05-12 | 2004-11-18 | Moore Bob M. | Method and kit for regulation of microvascular tone |
WO2004105699A2 (fr) * | 2003-05-28 | 2004-12-09 | Pharmacia Corporation | Compositions renfermant un inhibiteur selectif de la cyclooxygenase-2 et un agent cannabinoide servant au traitement de lesions du systeme nerveux central |
US20070203209A1 (en) * | 2005-08-18 | 2007-08-30 | Wilmin Bartolini | Useful indole compounds |
WO2007140786A1 (fr) * | 2006-06-08 | 2007-12-13 | Neurokey A/S | Utilisation de médicaments qui induisent une hypothermie |
WO2008040360A2 (fr) * | 2006-10-04 | 2008-04-10 | Neurokey A/S | Utilisation de médicaments induisant une hypothermie |
WO2008116816A1 (fr) * | 2007-03-26 | 2008-10-02 | Glaxo Group Limited | Combinaison de ligand de cb2 et de paracetamol |
WO2009071095A2 (fr) * | 2007-12-05 | 2009-06-11 | Neurokey A/S | Prévention d'hyperthermie suite au traitement hypothermique d'une ischémie |
-
2009
- 2009-04-08 WO PCT/DK2009/000092 patent/WO2009124553A2/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837228A (en) * | 1979-05-31 | 1989-06-06 | The University Of Mississippi | Antiinflammatory and antimicrobial compounds and compositions |
WO2001024645A1 (fr) * | 1999-10-07 | 2001-04-12 | Societe Des Produits Nestle S.A. | Composition nutritionnelle |
WO2004004702A2 (fr) * | 2002-07-09 | 2004-01-15 | The Scripps Research Institute | Procede pour empecher les lesions par ischemie et reperfusion |
US20040229850A1 (en) * | 2003-05-12 | 2004-11-18 | Moore Bob M. | Method and kit for regulation of microvascular tone |
WO2004105699A2 (fr) * | 2003-05-28 | 2004-12-09 | Pharmacia Corporation | Compositions renfermant un inhibiteur selectif de la cyclooxygenase-2 et un agent cannabinoide servant au traitement de lesions du systeme nerveux central |
US20070203209A1 (en) * | 2005-08-18 | 2007-08-30 | Wilmin Bartolini | Useful indole compounds |
WO2007140786A1 (fr) * | 2006-06-08 | 2007-12-13 | Neurokey A/S | Utilisation de médicaments qui induisent une hypothermie |
WO2008040360A2 (fr) * | 2006-10-04 | 2008-04-10 | Neurokey A/S | Utilisation de médicaments induisant une hypothermie |
WO2008116816A1 (fr) * | 2007-03-26 | 2008-10-02 | Glaxo Group Limited | Combinaison de ligand de cb2 et de paracetamol |
WO2009071095A2 (fr) * | 2007-12-05 | 2009-06-11 | Neurokey A/S | Prévention d'hyperthermie suite au traitement hypothermique d'une ischémie |
Non-Patent Citations (4)
Title |
---|
AHN ET AL: "Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 132, no. 1-2, 3 October 2007 (2007-10-03), pages 23 - 32, XP022283606, ISSN: 0304-3959 * |
GUINDON J ET AL: "Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides?", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 550, no. 1-3, 21 November 2006 (2006-11-21), pages 68 - 77, XP025170094, ISSN: 0014-2999, [retrieved on 20061121] * |
LEKER RONEN R ET AL: "Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 34, no. 8, 1 August 2003 (2003-08-01), pages 2000 - 2006, XP002451424, ISSN: 0039-2499 * |
SLIVA JIRI ET AL: "Analgesic efficacy of CP 55940 in combination with diclofenac in rodents", ACTA PHARMACOLOGICA SINICA, vol. 27, no. Suppl. 1, July 2006 (2006-07-01), & 15TH WORLD CONGRESS OF PHARMACOLOGY; BEIJING, PEOPLES R CHINA; JULY 02 07, 2006, pages 113, XP009123932, ISSN: 1671-4083 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
Also Published As
Publication number | Publication date |
---|---|
WO2009124553A2 (fr) | 2009-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009124553A3 (fr) | Utilisation de médicaments induisant une hypothermie | |
IL195560A0 (en) | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia | |
IL205704A (en) | Use of alpha adrenoceptor inhibitors in the preparation of a drug for the treatment of pig fever | |
IL216582A0 (en) | Composition for use in decreasing the transmission of human pathogens, devices comprising the same and uses thereof | |
ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
EP2306994A4 (fr) | Agonistes du récepteur s1p1 et utilisations | |
IL213168A0 (en) | 1,2,4-oxadiazole derivatives and their therapeutic use | |
HK1159108A1 (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof | |
IL197553A0 (en) | Use of hypothermia inducing drugs | |
AU2009223153A8 (en) | Use of GABAa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness | |
WO2011156479A3 (fr) | Agonistes trkb et leurs procédés d'utilisation | |
IL209840A0 (en) | Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors | |
ZA201002113B (en) | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators | |
IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
IL226370A (en) | Cannabinoid receptor antagonists used to treat metabolic disorders including obesity and diabetes | |
IL201416A0 (en) | Triazolopyridine carboxamide derivatives, preparation thereof and theraputic use thereof | |
IL207629A0 (en) | Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof | |
HK1188138A1 (en) | Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension a1 | |
EP2209377A4 (fr) | Utilisation d'agonistes et de précurseurs de récepteurs de la vitamine d pour traiter la fibrose | |
IL217300A0 (en) | Pyrazole derivatives' prepartion thereof, and therapeutic use thereof | |
HK1252981A1 (zh) | 作為用於治療數種疾病如抑鬱症、糖尿病和帕金森病的taar調節劑的吡唑甲酰胺衍生物 | |
HK1166493A1 (zh) | 維生素 受體激動劑及其用途 | |
HK1164861A1 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
ZA200900120B (en) | Use of cannabinoid receptor agaonists as hypothermia inducing drugs for the treatment of ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 07/02/2011) |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09730274 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09730274 Country of ref document: EP Kind code of ref document: A2 |